CureVac vs. BioNTech/Pfizer: mRNA Patent Dispute Ends in Mutual Dismissal

Case Overview

Introduction

In one of the most closely watched mRNA patent disputes since the COVID-19 vaccine era, CureVac SE’s infringement action against BioNTech SE — with Pfizer, Inc. and BioNTech Manufacturing GmbH as counterclaim parties — concluded with a mutual dismissal with prejudice in the Eastern District of Virginia. Filed on May 19, 2023, and closed on August 7, 2025 (Case No. 2:23-cv-00222), the case spanned 811 days and involved seven patents covering core mRNA technology, including nucleic acid optimization, RNA purification, and coronavirus vaccine formulations.

The outcome — a negotiated bilateral dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii) — carries significant weight for mRNA patent litigation strategy. Neither side secured a judicial ruling on infringement or validity, yet both sides surrendered substantial legal positions permanently. For patent attorneys, IP professionals, and R&D teams operating in the mRNA space, this case offers critical lessons about portfolio management, litigation risk, and the commercial calculus driving settlements in high-value biotech patent disputes.

The Parties

The Patents at Issue

Seven U.S. patents formed the core of CureVac’s infringement assertions:

• • US11135312B2 — Stabilized, translation-optimized mRNA
• • US11149278B2 — RNA purification via tangential flow filtration
• • US10760070B2 — Pharmaceutical compositions with optimized coding regions
• • US11241493B2 — Artificial nucleic acid molecules for protein expression
• • US11471525B2 — mRNA stability and translation enhancement
• • US11576966B2 — Nucleic acid optimization
• • US11596686B2 — Coronavirus vaccine formulations

The Accused Products

CureVac alleged infringement based on BioNTech’s technologies underlying: (1) artificial nucleic acid molecules for improved protein expression; (2) coronavirus vaccines; (3) RNA purification methods using tangential flow filtration; and (4) pharmaceutical compositions with stabilized, translation-optimized mRNA. These technologies sit at the commercial core of the BNT162b2 program.

Legal Representation

Plaintiff (CureVac): Duane Morris LLP, Marshall Gerstein & Borun LLP, MoloLamken LLP, and Spotts Fain PC — a formidable multi-firm coalition combining patent prosecution expertise with appellate and trial capabilities.

Defendant (BioNTech): Paul Hastings LLP, Winston & Strawn LLP, Kaufman & Canoles PC, and Saul Ewing LLP — an equally robust defense consortium with deep pharmaceutical patent litigation experience.

The Verdict & Legal Analysis

Litigation Timeline & Procedural History

CureVac filed suit on May 19, 2023, in the Eastern District of Virginia — a venue known for its “Rocket Docket” reputation for expeditious case management, a strategic choice signaling CureVac’s intent to move aggressively. The case proceeded at the district court (first instance) level without proceeding to trial.

The litigation ran for 811 days — substantially longer than a typical E.D. Va. patent case — suggesting that the complexity of seven multi-claim patents, the technical sophistication of mRNA science, and the commercial magnitude of the dispute (billions in COVID-19 vaccine revenues at stake) necessitated extended discovery, expert development, and motion practice.

The amended complaint (ECF No. 106) added or restructured infringement counts, while BioNTech’s counterclaims (ECF No. 116) asserted both non-infringement declarations and invalidity challenges across all seven patents plus additional patents (‘493, ‘525, ‘966). The breadth of BioNTech’s invalidity counterclaims — targeting ten patents — indicates a comprehensive prior art and prosecution history challenge strategy.

No chief judge data was specified in the record. The case closed on August 7, 2025.

Outcome

The case terminated via mutual stipulated dismissal with prejudice under Fed. R. Civ. P. 41(a)(1)(A)(ii). Critically:

• • CureVac dismissed with prejudice all infringement claims across seven patents.
• • BioNTech/Pfizer dismissed with prejudice all counterclaims for declarations of non-infringement (ten patents) and all invalidity counterclaims (ten patents).

No damages figure was publicly disclosed. No injunctive relief was granted or denied by the court. The dismissal with prejudice bars any party from re-litigating these specific claims in federal court.

Verdict Cause Analysis

The case was structured as a classic offensive patent assertion by CureVac paired with defensive invalidity and non-infringement counterclaims by BioNTech — a pattern common in pharmaceutical patent disputes where the defendant seeks a clean judicial record.

The mutual nature of the dismissal is legally significant. BioNTech surrendered its invalidity counterclaims — positions that, if successful, would have extinguished CureVac’s patents entirely and benefited the broader industry. This suggests BioNTech’s primary objective was commercial resolution rather than creating defensive precedent. Conversely, CureVac abandoned its infringement positions, forgoing any damages from one of the most commercially valuable vaccine programs in history.

No published claim construction order or summary judgment ruling is identified in the available record, which suggests the case resolved during the pre-trial phase — potentially following early claim construction briefing that revealed significant litigation risk on both sides.

Legal Significance

The dismissal with prejudice on both infringement and invalidity creates a nuanced precedential posture:

• • No invalidity ruling means CureVac’s seven patents survive with full presumption of validity under 35 U.S.C. § 282 — preserving their value for future assertion against other parties.
• • No infringement ruling means BioNTech received no judicial declaration protecting its technology from future CureVac claims in different venues or against different product generations.
• • The ‘493, ‘525, and ‘966 patents — subjects of BioNTech’s counterclaims but not asserted by CureVac in the amended complaint — represent a potentially important portfolio element CureVac preserved without litigation exposure.